TradingMenu expanded
Forge Markets Forge Pro Browse Companies
DataMenu expanded
Forge Data Private Market Index Forge Accuidity Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News Tech IPO Calendar for 2024
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Forge Pro
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
Forge Accuidity Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
Tech IPO Calendar for 2024
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / Sionna Therapeutics Stock

Sionna Therapeutics Stock

www.sionnatx.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $331.32MM

Sionna Therapeutics is a life science company that aims to develop treatments for cystic fibrosis, which is a genetic disorder that affects the functioning of the lungs, pancreas, and other organs. Sionna Therapeutics was founded in 2019 and is headquartered in Boston, MA. The company researches drug treatments for the disorder striving to restore the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The CFTR protein is essential for the regulation of salt and water balance in the body.

Buy or sell Sionna Therapeutics stockLearn more about Sionna Therapeutics IPO

Register To Buy and Sell Shares

For more details on financing and valuation for Sionna Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Sionna Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Sionna Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Sionna Therapeutics investors also invested in these private companies

Viking Global Investors
Atlas Venture
Ra Capital Management
T. Rowe Price
Qatar Investment Authority
Perceptive Advisors
TPG
Cystic Fibrosis Foundation
OrbiMed
Enavate Sciences

Team

Management Team

Mike Cloonan
Chief Executive Officer & President
Vanya Sagar
Chief People Officer
John Macor Ph.D
Chief Scientific Officer
Greg Hurlbut Ph.D
Co-Founder & Senior Vice President of Discovery Research
Mark Munson Ph.D
Co-Founder & Vice President of Medicinal Chemistry
Charlotte McKee MD
Chief Medical Officer
Elena Ridloff
Chief Financial Officer & Head of Corporate Development

Board Members

Bruce Booth Ph.D
Atlas Venture
Edward Fleming MD
Enavate Sciences
Lucian Iancovici MD
TPG

Frequently Asked Questions About Sionna Therapeutics’ Stock

plusminus
Can you buy Sionna Therapeutics’ stock?
Sionna Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Sionna Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Sionna Therapeutics’ stock?
Yes, you can sell stock of a private company like Sionna Therapeutics. Forge can help you sell your Sionna Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Sionna Therapeutics’ stock price?
Sionna Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Sionna Therapeutics’ private market stock price with Forge Data.
plusminus
What is Sionna Therapeutics’ stock ticker symbol?
Sionna Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Other companies like Sionna Therapeutics in the BioTech & Pharma sector

Egenesis

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$387.57MM

Colossal Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B

Prime Medicine

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.23B

ADARx Pharmaceuticals

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$827.77MM

Altos Labs

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$6.33B

Tempus

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$8.7B

Pendulum Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$308.05MM

Cytonics

Sector
Healthcare / BioTech & Pharma
 
 

AI Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$110MM

News Highlights

Fierce Biotech 03/06/2024
Sionna secures $182M series C to more than double its clinical-stage cystic fibrosis contenders
To continue developing its treatment of cystic fibrosis, Sionna Therapeutics raised $182 million.

Trending Companies

Frequently Asked Questions

Updated on: Apr 27, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.